Tenderwize
Retour à la recherche

Non-exclusive Drug Discount Agreement for Liraglutid

AOK PLUS - Die Gesundheitskasse für Sachsen und Thüringen·Erfurt, Germany·Deadline Jun 30, 2027 · 306 days left·Open·Supplies·Framework
Inscrivez-vous pour sauvegarderOpen documents
Structured notice only
Titre original de l'avis

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Liraglutid (ATC-Code nach WHO: A10BJ02; amtlicher ATC: A10BJ02)

50/100

Score d'opportunité

Needs reviewLow complexity
SuppliesFrameworkOpen
Pourquoi ce score ?

Opportunité

50 / 100

Complexité

20 / 100

Facteurs de risque

No minimum purchase quantities; actual demand depends on unpredictable factors (prescriptions, pharmacy behavior). Reve...

Buyer reserves the right to terminate the open-house process early if exclusive agreements are concluded (typical 8-12...

Analyse approfondie du portefeuille

Analyse approfondie de l'adéquation entreprise

Utilise:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Aperçu

Moderate opportunity

Faits clés

  • Framework procurement
  • Supplies contract
  • 1 lot
  • Duration until Jun 2027
  • Conclusion of non-exclusive discount agreements for the supply of Liraglutid (ATC A10BJ02) to the AOK PLUS health insurance.
  • Open-house model: all qualified pharmaceutical companies can participate at any time during the participation period.
Afficher le résumé complet

Non-exclusive drug discount agreement for the active substance Liraglutid (ATC A10BJ02) under German social law (§ 130a Abs. 8 SGB V), using an open-house model. The agreement is open to all qualified pharmaceutical companies, with no exclusivity. No estimated value or guaranteed purchase quantities are provided. The agreement ends on 30 June 2027.

Risques

No minimum purchase quantities; actual demand depends on unpredictable factors (prescriptions, pharmacy behavior). Reve...

Buyer reserves the right to terminate the open-house process early if exclusive agreements are concluded (typical 8-12...

L'analyse peut être incomplète

Seule une partie des documents de consultation a été analysée. Des exigences, certificats ou documents de soumission supplémentaires peuvent exister dans les documents restants.

Exigences clés

Technical

  • Must be a pharmaceutical company as defined in § 4 Abs. 18 AMG with respect to the offered product.
  • Company seat must be in Germany, EU, or EEA.

Eligibility

  • Submit required declarations (exclusion grounds, Russia sanctions).

Les exigences peuvent être incomplètes.

Critères d'attribution

Lot 1

No explicit award criteria described; likely based on the offered discount percentage.

Acheteur

Localisation

Erfurt, DEU

Profil acheteur

Ouvrir le profil

Identifiant

DE256878834

Activité

Health

Lots (1)

LOT-0001

Non-exclusive Drug Discount Agreement for Liraglutid

Open-house model for concluding non-exclusive discount agreements on pharmaceuticals containing Liraglutid (ATC A10BJ02). No guaranteed volumes, no exclusivity. Multiple submissions possible during the participation period.

SuppliesFrameworkEU fundedElectronic submission

Localisation

Dresden, Germany

Durée

Jun 2026 - Jun 2027

Catégorie

Pharmaceutical products

Critères d'attribution

No explicit award criteria described; likely based on the offered discount percentage.

Date limite

Deadline Jun 30, 2027

Détails de la procédure

Date de publication
05 May 2026
Langues
German

Métadonnées de référence

Base juridique
32014L0024

Identifiants de référence

ID de l'appel d'offres
309108-2026

Documents (1)

Document de consultation 1

Appels d'offres similaires

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta

Aug 30